{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T12:09:07Z","timestamp":1792238947371,"version":"4.4.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,1,16]],"date-time":"2021-01-16T00:00:00Z","timestamp":1610755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,16]],"date-time":"2021-01-16T00:00:00Z","timestamp":1610755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Beirne Carter Center Immunology Training Grant","award":["T32AI007496"],"award-info":[{"award-number":["T32AI007496"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA057653"],"award-info":[{"award-number":["R01 CA057653"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cancer Research Institute","award":["Clinical Laboratory and Integration Project"],"award-info":[{"award-number":["Clinical Laboratory and Integration Project"]}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA44579"],"award-info":[{"award-number":["P30 CA44579"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Rebecca Clary Harris Fellowship"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s00262-020-02844-w","type":"journal-article","created":{"date-parts":[[2021,1,16]],"date-time":"2021-01-16T20:02:30Z","timestamp":1610827350000},"page":"2151-2164","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Characterization and comparison of innate and adaptive immune responses at vaccine sites in melanoma vaccine clinical trials"],"prefix":"10.1007","volume":"70","author":[{"given":"Marit M.","family":"Melssen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karlyn E.","family":"Pollack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max O.","family":"Meneveau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E.","family":"Smolkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Pinczewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander F.","family":"Koeppel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Sol-Church","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Hickman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna H.","family":"Deacon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina R.","family":"Petroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6664-4373","authenticated-orcid":false,"suffix":"Jr","given":"Craig L.","family":"Slingluff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,16]]},"reference":[{"key":"2844_CR1","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.1158\/1078-0432.ccr-10-3126","volume":"17","author":"MA Cheever","year":"2011","unstructured":"Cheever MA, Higano CS (2011) PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res 17:3520\u20133526. https:\/\/doi.org\/10.1158\/1078-0432.ccr-10-3126","journal-title":"Clin Cancer Res"},{"key":"2844_CR2","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1056\/NEJMoa1012863","volume":"364","author":"DJ Schwartzentruber","year":"2011","unstructured":"Schwartzentruber DJ, Lawson DH, Richards JM et al (2011) gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 364:2119\u20132127","journal-title":"N Engl J Med"},{"key":"2844_CR3","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1097\/CJI.0b013e3181e311ac","volume":"33","author":"CL Slingluff Jr","year":"2010","unstructured":"Slingluff CL Jr, Petroni GR, Smolkin ME et al (2010) Immunogenicity for CD8+ and CD4+ T cells of two formulations of an incomplete Freund\u2019s adjuvant for multipeptide melanoma vaccines. J Immunother 33:630\u2013638. https:\/\/doi.org\/10.1097\/CJI.0b013e3181e311ac","journal-title":"J Immunother"},{"key":"2844_CR4","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1097\/PPO.0b013e3181eaca65","volume":"16","author":"S Gnjatic","year":"2010","unstructured":"Gnjatic S, Sawhney NB, Bhardwaj N (2010) Toll-like receptor agonists: are they good adjuvants? Cancer J 16:382\u2013391","journal-title":"Cancer J"},{"key":"2844_CR5","doi-asserted-by":"publisher","first-page":"5854","DOI":"10.1016\/j.vaccine.2019.08.005","volume":"37","author":"RN Hyer","year":"2019","unstructured":"Hyer RN, Janssen RS (2019) Immunogenicity and safety of a 2-dose hepatitis B vaccine, HBsAg\/CpG 1018, in persons with diabetes mellitus aged 60\u201370years. Vaccine 37:5854\u20135861. https:\/\/doi.org\/10.1016\/j.vaccine.2019.08.005","journal-title":"Vaccine"},{"key":"2844_CR6","doi-asserted-by":"publisher","first-page":"6497","DOI":"10.1158\/1078-0432.ccr-12-2189","volume":"18","author":"P Sabbatini","year":"2012","unstructured":"Sabbatini P, Tsuji T, Ferran L et al (2012) Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clin Cancer Res 18:6497\u20136508. https:\/\/doi.org\/10.1158\/1078-0432.ccr-12-2189","journal-title":"Clin Cancer Res"},{"key":"2844_CR7","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s40425-019-0625-x","volume":"7","author":"MM Melssen","year":"2019","unstructured":"Melssen MM, Petroni GR, Chianese-Bullock KA et al (2019) A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund\u2019s adjuvant in melanoma patients. J Immunother Cancer 7:163. https:\/\/doi.org\/10.1186\/s40425-019-0625-x","journal-title":"J Immunother Cancer"},{"key":"2844_CR8","doi-asserted-by":"publisher","first-page":"e1216290","DOI":"10.1080\/2162402x.2016.1216290","volume":"5","author":"P Baumgaertner","year":"2016","unstructured":"Baumgaertner P, Costa Nunes C, Cachot A et al (2016) Vaccination of stage III\/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8(+) and CD4(+) T-cell responses with multiple specificities including a novel DR7-restricted epitope. Oncoimmunology 5:e1216290. https:\/\/doi.org\/10.1080\/2162402x.2016.1216290","journal-title":"Oncoimmunology"},{"key":"2844_CR9","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1172\/JCI23373","volume":"115","author":"DE Speiser","year":"2005","unstructured":"Speiser DE, Lienard D, Rufer N, Rubio-Godoy V, Rimoldi D, Lejeune F, Krieg AM, Cerottini JC, Romero P (2005) Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 115:739\u2013746","journal-title":"J Clin Invest"},{"key":"2844_CR10","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nm.3105","volume":"19","author":"Y Hailemichael","year":"2013","unstructured":"Hailemichael Y, Dai Z, Jaffarzad N et al (2013) Persistent antigen at vaccination sites induces tumor-specific CD8(+) T cell sequestration, dysfunction and deletion. Nat Med 19:465\u2013472","journal-title":"Nat Med"},{"key":"2844_CR11","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1200\/JCO.2012.43.7111","volume":"31","author":"WH Kruit","year":"2013","unstructured":"Kruit WH, Suciu S, Dreno B et al (2013) Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. J Clin Oncol 31:2413\u20132420","journal-title":"J Clin Oncol"},{"key":"2844_CR12","doi-asserted-by":"crossref","unstructured":"Kruit WH, Suciu S, Dreno B, et al (2008) Immunization with recombinant MAGE-A3 protein combined with adjuvant systems AS15 or AS02B in patients with unresectable and progressive metastatic cutaneous melanoma: A randomized open-label phase II study of the EORTC Melanoma Group (16032\u201318031). J Clin Oncol 26: abstract 9065.","DOI":"10.1200\/jco.2008.26.15_suppl.9065"},{"key":"2844_CR13","doi-asserted-by":"publisher","first-page":"e000068","DOI":"10.1136\/esmoopen-2016-000068","volume":"1","author":"R Gutzmer","year":"2016","unstructured":"Gutzmer R, Rivoltini L, Levchenko E et al (2016) Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study. ESMO Open 1:e000068. https:\/\/doi.org\/10.1136\/esmoopen-2016-000068","journal-title":"ESMO Open"},{"key":"2844_CR14","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/s1470-2045(16)00099-1","volume":"17","author":"JF Vansteenkiste","year":"2016","unstructured":"Vansteenkiste JF, Cho BC, Vanakesa T et al (2016) Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 17:822\u2013835. https:\/\/doi.org\/10.1016\/s1470-2045(16)00099-1","journal-title":"Lancet Oncol"},{"key":"2844_CR15","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/s1470-2045(18)30254-7","volume":"19","author":"B Dreno","year":"2018","unstructured":"Dreno B, Thompson JF, Smithers BM et al (2018) MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 19:916\u2013929. https:\/\/doi.org\/10.1016\/s1470-2045(18)30254-7","journal-title":"Lancet Oncol"},{"key":"2844_CR16","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00262-015-1770-9","volume":"65","author":"CL Slingluff Jr","year":"2016","unstructured":"Slingluff CL Jr, Petroni GR, Olson WC et al (2016) A randomized pilot trial testing the safety and immunologic effects of a MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal\/subcutaneous sites. Cancer Immunol Immunother 65:25\u201336. https:\/\/doi.org\/10.1007\/s00262-015-1770-9","journal-title":"Cancer Immunol Immunother"},{"key":"2844_CR17","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1245\/s10434-014-3794-3","volume":"21","author":"Y Hu","year":"2014","unstructured":"Hu Y, Smolkin ME, White EJ, Petroni GR, Neese PY, Slingluff CL Jr (2014) Inflammatory adverse events are associated with disease-free survival after vaccine therapy among patients with melanoma. Ann Surg Oncol 21:3978\u20133984. https:\/\/doi.org\/10.1245\/s10434-014-3794-3","journal-title":"Ann Surg Oncol"},{"key":"2844_CR18","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1007\/s00262-013-1435-5","volume":"62","author":"EP Salerno","year":"2013","unstructured":"Salerno EP, Shea SM, Olson WC, Petroni GR, Smolkin ME, McSkimming C, Chianese-Bullock KA, Slingluff CL Jr (2013) Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete Freund\u2019s adjuvant, with or without peptide. Cancer Immunol Immunother 62:1149\u20131159. https:\/\/doi.org\/10.1007\/s00262-013-1435-5","journal-title":"Cancer Immunol Immunother"},{"key":"2844_CR19","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1479-5876-8-79","volume":"8","author":"JT Schaefer","year":"2010","unstructured":"Schaefer JT, Patterson JW, Deacon DH, Smolkin ME, Petroni GR, Jackson EM, Slingluff CL Jr (2010) Dynamic changes in cellular infiltrates with repeated cutaneous vaccination: a histologic and immunophenotypic analysis. J Transl Med 8:79. https:\/\/doi.org\/10.1186\/1479-5876-8-79","journal-title":"J Transl Med"},{"key":"2844_CR20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00262-015-1770-9","volume":"65","author":"CL Slingluff Jr","year":"2016","unstructured":"Slingluff CL Jr, Petroni GR, Olson WC et al (2016) A randomized pilot trial testing the safety and immunologic effects of a MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal\/subcutaneous sites. Cancer Immunol Immunother 65:25\u201336. https:\/\/doi.org\/10.1007\/s00262-015-1770-9","journal-title":"Cancer Immunol Immunother"},{"key":"2844_CR21","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1097\/CJI.0b013e31823731a4","volume":"35","author":"RC Harris","year":"2012","unstructured":"Harris RC, Chianese-Bullock KA, Petroni GR, Schaefer JT, Brill LB 2nd, Molhoek KR, Deacon DH, Patterson JW, Slingluff CL Jr (2012) The vaccine-site microenvironment induced by injection of incomplete Freund\u2019s adjuvant, with or without melanoma peptides. J Immunother 35:78\u201388. https:\/\/doi.org\/10.1097\/CJI.0b013e31823731a4","journal-title":"J Immunother"},{"key":"2844_CR22","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nmeth.4197","volume":"14","author":"R Patro","year":"2017","unstructured":"Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C (2017) Salmon provides fast and bias-aware quantification of transcript expression. Nat Methods 14:417\u2013419. https:\/\/doi.org\/10.1038\/nmeth.4197","journal-title":"Nat Methods"},{"key":"2844_CR23","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15:550. https:\/\/doi.org\/10.1186\/s13059-014-0550-8","journal-title":"Genome Biol"},{"key":"2844_CR24","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc B 57:289\u2013300","journal-title":"J Roy Stat Soc B"},{"key":"2844_CR25","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/1471-2105-10-161","volume":"10","author":"W Luo","year":"2009","unstructured":"Luo W, Friedman MS, Shedden K, Hankenson KD, Woolf PJ (2009) GAGE: generally applicable gene set enrichment for pathway analysis. BMC Bioinform 10:161. https:\/\/doi.org\/10.1186\/1471-2105-10-161","journal-title":"BMC Bioinform"},{"key":"2844_CR26","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/nri3298","volume":"12","author":"JP Girard","year":"2012","unstructured":"Girard JP, Moussion C, F\u00f6rster R (2012) HEVs, lymphatics and homeostatic immune cell trafficking in lymph nodes. Nat Rev Immunol 12:762\u2013773. https:\/\/doi.org\/10.1038\/nri3298","journal-title":"Nat Rev Immunol"},{"key":"2844_CR27","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/srep00765","volume":"2","author":"JL Messina","year":"2012","unstructured":"Messina JL, Fenstermacher DA, Eschrich S et al (2012) 12-Chemokine Gene Signature Identifies Lymph Node-like Structures in Melanoma: Potential for Patient Selection for Immunotherapy? Sci Rep 2:765. https:\/\/doi.org\/10.1038\/srep00765","journal-title":"Sci Rep"},{"key":"2844_CR28","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10875-005-4091-5","volume":"25","author":"MV Jonsson","year":"2005","unstructured":"Jonsson MV, Szodoray P, Jellestad S, Jonsson R, Skarstein K (2005) Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sj\u00f6gren\u2019s syndrome. J Clin Immunol 25:189\u2013201. https:\/\/doi.org\/10.1007\/s10875-005-4091-5","journal-title":"J Clin Immunol"},{"key":"2844_CR29","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1002\/eji.201242656","volume":"42","author":"JL Grogan","year":"2012","unstructured":"Grogan JL, Ouyang W (2012) A role for Th17 cells in the regulation of tertiary lymphoid follicles. Eur J Immunol 42:2255\u20132262. https:\/\/doi.org\/10.1002\/eji.201242656","journal-title":"Eur J Immunol"},{"key":"2844_CR30","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3389\/fimmu.2016.00477","volume":"7","author":"F Barone","year":"2016","unstructured":"Barone F, Gardner DH, Nayar S, Steinthal N, Buckley CD, Luther SA (2016) Stromal fibroblasts in tertiary lymphoid structures: a novel target in chronic inflammation. Front Immunol 7:477. https:\/\/doi.org\/10.3389\/fimmu.2016.00477","journal-title":"Front Immunol"},{"key":"2844_CR31","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1136\/annrheumdis-2016-209217","volume":"76","author":"F Ciccia","year":"2017","unstructured":"Ciccia F, Rizzo A, Maugeri R et al (2017) Ectopic expression of CXCL13, BAFF, APRIL and LT-beta is associated with artery tertiary lymphoid organs in giant cell arteritis. Ann Rheum Dis 76:235\u2013243. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209217","journal-title":"Ann Rheum Dis"},{"key":"2844_CR32","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.3389\/fimmu.2018.01952","volume":"9","author":"E Pipi","year":"2018","unstructured":"Pipi E, Nayar S, Gardner DH, Colafrancesco S, Smith C, Barone F (2018) Tertiary lymphoid structures: autoimmunity goes local. Front Immunol 9:1952. https:\/\/doi.org\/10.3389\/fimmu.2018.01952","journal-title":"Front Immunol"},{"key":"2844_CR33","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/bs.acr.2015.04.003","volume":"128","author":"AM Weinstein","year":"2015","unstructured":"Weinstein AM, Storkus WJ (2015) Therapeutic lymphoid organogenesis in the tumor microenvironment. Adv Cancer Res 128:197\u2013233. https:\/\/doi.org\/10.1016\/bs.acr.2015.04.003","journal-title":"Adv Cancer Res"},{"key":"2844_CR34","doi-asserted-by":"publisher","first-page":"271","DOI":"10.4110\/in.2016.16.5.271","volume":"16","author":"F Jing","year":"2016","unstructured":"Jing F, Choi EY (2016) Potential of cells and cytokines\/chemokines to regulate tertiary lymphoid structures in human diseases. Immune Netw 16:271\u2013280. https:\/\/doi.org\/10.4110\/in.2016.16.5.271","journal-title":"Immune Netw"},{"key":"2844_CR35","doi-asserted-by":"publisher","first-page":"432","DOI":"10.4049\/jimmunol.1701269","volume":"200","author":"VH Engelhard","year":"2018","unstructured":"Engelhard VH, Rodriguez AB, Mauldin IS, Woods AN, Peske JD, Slingluff CL Jr (2018) Immune cell infiltration and tertiary lymphoid structures as determinants of antitumor immunity. J Immunol 200:432\u2013442. https:\/\/doi.org\/10.4049\/jimmunol.1701269","journal-title":"J Immunol"},{"key":"2844_CR36","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000544","author":"KE Pollack","year":"2020","unstructured":"Pollack KE, Meneveau MO, Melssen MM et al (2020) Incomplete Freund\u2019s adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2020-000544","journal-title":"J Immunother Cancer"},{"key":"2844_CR37","doi-asserted-by":"publisher","first-page":"816","DOI":"10.3389\/fimmu.2019.00816","volume":"10","author":"SJ Berendam","year":"2019","unstructured":"Berendam SJ, Koeppel AF, Godfrey NR et al (2019) Comparative transcriptomic analysis identifies a range of immunologically related functional elaborations of lymph node associated lymphatic and blood endothelial cells. Front Immunol 10:816. https:\/\/doi.org\/10.3389\/fimmu.2019.00816","journal-title":"Front Immunol"},{"key":"2844_CR38","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.coi.2008.04.001","volume":"20","author":"K Takatsu","year":"2008","unstructured":"Takatsu K, Nakajima H (2008) IL-5 and eosinophilia. Curr Opin Immunol 20:288\u2013294. https:\/\/doi.org\/10.1016\/j.coi.2008.04.001","journal-title":"Curr Opin Immunol"},{"key":"2844_CR39","doi-asserted-by":"publisher","first-page":"7037","DOI":"10.1073\/pnas.1202288109","volume":"109","author":"LK Mackay","year":"2012","unstructured":"Mackay LK, Stock AT, Ma JZ, Jones CM, Kent SJ, Mueller SN, Heath WR, Carbone FR, Gebhardt T (2012) Long-lived epithelial immunity by tissue-resident memory T (TRM) cells in the absence of persisting local antigen presentation. Proc Natl Acad Sci U S A 109:7037\u20137042","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2844_CR40","doi-asserted-by":"publisher","first-page":"9525","DOI":"10.1038\/s41598-017-09909-4","volume":"7","author":"S Haddadi","year":"2017","unstructured":"Haddadi S, Thanthrige-Don N, Afkhami S, Khera A, Jeyanathan M, Xing Z (2017) Expression and role of VLA-1 in resident memory CD8 T cell responses to respiratory mucosal viral-vectored immunization against tuberculosis. Sci Rep 7:9525. https:\/\/doi.org\/10.1038\/s41598-017-09909-4","journal-title":"Sci Rep"},{"key":"2844_CR41","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1038\/ni.2744","volume":"14","author":"LK Mackay","year":"2013","unstructured":"Mackay LK, Rahimpour A, Ma JZ et al (2013) The developmental pathway for CD103(+)CD8+ tissue-resident memory T cells of skin. Nat Immunol 14:1294\u20131301","journal-title":"Nat Immunol"},{"key":"2844_CR42","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.it.2012.04.006","volume":"33","author":"K Neyt","year":"2012","unstructured":"Neyt K, Perros F, GeurtsvanKessel CH, Hammad H, Lambrecht BN (2012) Tertiary lymphoid organs in infection and autoimmunity. Trends Immunol 33:297\u2013305. https:\/\/doi.org\/10.1016\/j.it.2012.04.006","journal-title":"Trends Immunol"},{"key":"2844_CR43","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1111\/j.1349-7006.2010.01687.x","volume":"101","author":"H Hayasaka","year":"2010","unstructured":"Hayasaka H, Taniguchi K, Fukai S, Miyasaka M (2010) Neogenesis and development of the high endothelial venules that mediate lymphocyte trafficking. Cancer Sci 101:2302\u20132308. https:\/\/doi.org\/10.1111\/j.1349-7006.2010.01687.x","journal-title":"Cancer Sci"},{"key":"2844_CR44","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3389\/fimmu.2016.00244","volume":"7","author":"N Hiraoka","year":"2016","unstructured":"Hiraoka N, Ino Y, Yamazaki-Itoh R (2016) Tertiary Lymphoid Organs in Cancer Tissues. Front Immunol 7:244. https:\/\/doi.org\/10.3389\/fimmu.2016.00244","journal-title":"Front Immunol"},{"key":"2844_CR45","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/imr.12405","volume":"271","author":"MC Dieu-Nosjean","year":"2016","unstructured":"Dieu-Nosjean MC, Giraldo NA, Kaplon H, Germain C, Fridman WH, Sautes-Fridman C (2016) Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers. Immunol Rev 271:260\u2013275. https:\/\/doi.org\/10.1111\/imr.12405","journal-title":"Immunol Rev"},{"key":"2844_CR46","first-page":"257","volume":"75","author":"M Cumberbatch","year":"1992","unstructured":"Cumberbatch M, Kimber I (1992) Dermal tumour necrosis factor-alpha induces dendritic cell migration to draining lymph nodes, and possibly provides one stimulus for Langerhans\u2019 cell migration. Immunology 75:257\u2013263","journal-title":"Immunology"},{"key":"2844_CR47","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/icb.2010.40","volume":"88","author":"BE Clausen","year":"2010","unstructured":"Clausen BE, Kel JM (2010) Langerhans cells: critical regulators of skin immunity? Immunol Cell Biol 88:351\u2013360. https:\/\/doi.org\/10.1038\/icb.2010.40","journal-title":"Immunol Cell Biol"},{"key":"2844_CR48","doi-asserted-by":"publisher","first-page":"743169","DOI":"10.1155\/2015\/743169","volume":"2015","author":"A Said","year":"2015","unstructured":"Said A, Weindl G (2015) Regulation of Dendritic Cell Function in Inflammation. J Immunol Res 2015:743169. https:\/\/doi.org\/10.1155\/2015\/743169","journal-title":"J Immunol Res"},{"key":"2844_CR49","doi-asserted-by":"publisher","first-page":"6386","DOI":"10.1158\/1078-0432.CCR-07-0486","volume":"13","author":"CL Slingluff Jr","year":"2007","unstructured":"Slingluff CL Jr, Petroni GR, Chianese-Bullock KA et al (2007) Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting. Clin Cancer Res 13:6386\u20136395. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-0486","journal-title":"Clin Cancer Res"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02844-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-020-02844-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02844-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T14:38:10Z","timestamp":1724337490000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-020-02844-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,16]]},"references-count":49,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["2844"],"URL":"https:\/\/doi.org\/10.1007\/s00262-020-02844-w","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,16]]},"assertion":[{"value":"29 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"C.L. Slingluff Jr. reports receiving commercial research grants from Merck, GlaxoSmithKline, 3\u00a0M, and Celldex; has ownership interest (including patents) in several of the peptides used in the 12MP vaccine with UVA Licensing and Ventures Group; and is a consultant\/advisory board member for Immatics, Curevac, and Polynoma. No potential conflicts of interest were disclosed by the other authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"Clinical trials Mel48 and Mel55 were performed with IRB (#13498 and #15398, respectively) and FDA approval and are registered with Clinicaltrials.gov under NCT00705640 (Mel48) and NCT01425749 (Mel55). Patients provided written informed consent to participate.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}